Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on
the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency
and height of major amputations in patients suffering from PAOD stage IV.